Clinical Trial Update: First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line combination of ipilimumab, nivolumab, and N-803 for stage IV or recurrent non-small cell lung cancer; the study is not yet r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Nogapendekin-alfa Inbakicept
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | Phase 2 | Status: NOT_YET_RECRUITING